On the stock market since 2000, it operates in the world of health and science. It has 11,085 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 37% below its peak. The market has trimmed its expectations for the company.
The company sells $3.4B a year; the problem isn’t sales — it’s costs running above that number.
It pays out $0.20 per share each year — regular cash for whoever holds the stock.
A loss of $8.6M against $3.4B in annual sales.
The stock trades 13% above the average analyst price target.
On our five-subject report card, BRKR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BRKR has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.